Pramlintide results: what to expect and when
A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.
Also called: Symlin, SymlinPen, Pramlintide acetate, AC137, AC-0137, Tripro-amylin.
Amylin analogues · Short-acting amylin receptor agonist · Evidence: Approved drug.
51 completed, terminated or active registered studies were found; 15 planned, withdrawn or unknown-status records were excluded. Early unregistered trials make this a minimum.
Key studies
- Early dose finding: 30–300 mcg: Meal glucose rises fell; the highest dose caused more nausea. (source)
- Four-week dose and meal timing: Several meal-based schedules improved short-term glucose markers. (source)
- Type 2 dose finding: Short-term glucose markers improved across the tested doses. (source)
- Type 1: one year plus extension: Pramlintide modestly improved glucose control without weight gain. (source)
- Type 1: 60 and 90 mcg: 60 mcg modestly improved HbA1c and weight over one year. (source)
- Type 1: fixed-insulin trial: This fixed-insulin trial showed a modest blood sugar effect. (source)
Related to Pramlintide
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
- CagriSema: An unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Download medicine data, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA: SYMLIN, NDA 021332, FDA
- FD&C Act Provisions that Apply to Human Drug Compounding, FDA · FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.